Please wait
0001061983S-3ASREX-FILING FEEStruefalseS-3S-3 0001061983 2025-02-27 2025-02-27 0001061983 1 2025-02-27 2025-02-27 0001061983 2 2025-02-27 2025-02-27 0001061983 3 2025-02-27 2025-02-27 0001061983 4 2025-02-27 2025-02-27 0001061983 5 2025-02-27 2025-02-27 0001061983 1 2025-02-27 2025-02-27 0001061983 2 2025-02-27 2025-02-27 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107
Calculation of Filing Fee Tables
Form S-3
(Form Type)
Cytokinetics, Incorporated
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
 
                         
    
Security
Type
  
Security
Class
Title
  
Fee
Calculation
or Carry
Forward
Rule
  
Amount
Registered
  
Proposed
Maximum
Offering
Price Per
Unit
  
Maximum
Aggregate
Offering
Price
  
Fee
Rate(4)
  
Amount of
Registration
Fee(4)
  
Carry
Forward
Form
Type
  
Carry
Forward
File
Number
  
Carry
Forward
Initial
effective
date
  
Filing Fee
Previously
Paid In
Connection
with Unsold
Securities to
be Carried
Forward
 
Newly Registered Securities
                         
Fees to Be
Paid
   Equity   Common Stock, $0.001 par value per share   Rule 456(b) and Rule 457(r)   (1)(2)   (3)   (3)   (4)   (4)          
                         
    Equity   Preferred Stock, $0.001 par value per share   Rule 456(b) and Rule 457(r)   (1)(2)   (3)   (3)   (4)   (4)          
                         
    Debt   Debt Securities   Rule 456(b) and Rule 457(r)   (1)(2)   (3)   (3)   (4)   (4)          
                         
    Other   Warrants   Rule 456(b) and Rule 457(r)   (1)(2)   (3)   (3)   (4)   (4)          
                         
    Equity   Common Stock, $0.001 par value per share  
Rule 457(o)
and (r)
   $500,000,000   N/A    $500,000,000    0.00015310   $76,550          
                         
Fees
Previously
Paid
   N/A   N/A   N/A   N/A     N/A     N/A          
 
Carry Forward Securities
                         
Carry
Forward
Securities
   N/A   N/A   N/A   N/A     N/A       N/A   N/A   N/A   N/A
                   
    Total Offering Amounts    (3)   $500,000,000   0.00015310   $76,550 (5)          
                   
    Total Fees Previously Paid          —          
                   
    Total Fee Offsets          $3,763          
                   
    Net Fee Due                $72,787                
 
1
Table 2: Fee Offset Claims and Sources
 
                       
    
Registrant or
Filer Name
  
Form
or
Filing
Type
  
File
Number
  
Initial
Filing
Date
  
Filing
Date
  
Fee Offset
Claimed
  
Security
Type
Associated
with Fee
Offset
Claimed
  
Security
Title
Associated
with Fee
Offset
Claimed
  
Unsold
Securities
Associated
with Fee
Offset
Claimed
  
Unsold
Aggregate
Offering
Amount
Associated
with Fee
Offset
Claimed
  
Fee Paid
with Fee
Offset
Source
 
Rule 457(p)
                       
Fee
Offset
Claims
   Cytokinetics, Incorporated  
424(b)(5)
 		  
333-268483
   March 1, 2023     $3,763   Equity   Common Stock, $0.001 par value per share   —   $34,150,650    
                       
Fee
Offset
Sources
   Cytokinetics, Incorporated  
424(b)(5)
 		  
333-268483
       March 1, 2023       Equity   Common Stock, $0.001 par value per share           $3,763(6)
 
(1)
The securities registered hereunder include such indeterminate number of (a) shares of common stock, (b) shares of preferred stock, (c) debt securities, (d) warrants to purchase common stock, preferred stock or other securities of the registrant, as may be sold from time to time by the registrant. There are also being registered hereunder an indeterminate number of shares of common stock and preferred stock as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance.
(2)
Pursuant to Rule 416 under the Securities Act of 1933, as amended, or the Securities Act, this registration statement shall also cover any additional shares of the registrant’s securities that become issuable by reason of any stock splits, stock dividend or similar transaction.
(3)
The proposed maximum per security and aggregate offering prices per class of securities will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security. Separate consideration may or may not be received for securities that are issuable on exercise, conversion or exchange of other securities.
(4)
In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the entire registration fee. In connection with the securities offered hereby, the registrant will pay
“pay-as-you-go
registration fees” in accordance with Rule 456(b) under the Securities Act. The registrant will calculate the registration fee applicable to an offer of securities pursuant to this registration statement based on the fee rate in effect on the date of such fee payment.
(5)
In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the entire registration fee other than the registration fee due in connection with $500,000,000 of shares of its common stock, $0.001 par value per share, that may be issued and sold from time to time under the sales agreement prospectus included herein. Any subsequent registration fees will be paid on
a pay-as-you-go basis.
(6)
On March 1, 2023, the registrant filed a prospectus supplement (the “
2023 Prospectus Supplement
”) to the prospectus included in its Registration Statement on
Form S-3 (Registration
Statement No. 333-268483) and
concurrently submitted a fee of $26,570. The 2023 Prospectus Supplement related to the registrant’s offer and sale from time to time of shares of the registrant’s common stock, par value $0.001 per share, having an aggregate gross sales price of up to $300,000,000 from time to time under a Controlled Equity Offering
SM
 Sales Agreement with Cantor Fitzgerald & Co. As of the date of this prospectus supplement, $34,150,650 remains unsold under the 2023 Prospectus Supplement. The offering that included the unsold securities under the 2023 Prospectus Supplement has been terminated. Pursuant to Rule 457(p) under the Securities Act, a registration fee credit of $3,763 is available to offset the current registration fee.
 
2